secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022103
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership
--------------------------------------------------------------------------------

- Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.
- Membership fee $99/month includes unlimited virtual visits, progress tracking, lifestyle coaching; GLP-1 meds from $499/month cash-pay.
- No insurance required; prescriptions fulfilled via LillyDirect Self Pay, NovoCare Pharmacy, or local pharmacies.
- Company highlights White House deal lowering government GLP-1 pricing to $245/month and $50 Medicare copays from mid-2026.
- CEO Jacob Cohen states program targets 42% of U.S. adults with obesity, aiming to make treatment simple and sustainable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/0001493152-25-022103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer